Lessons learned from the clinical development and market authorization of Glybera.

Human gene therapy. Clinical development

Volumn 24, Issue 2, 2013, Pages 55-64

  Bryant, Laura M ^a   Christopher, Devin M ^b   Giles, April R ^b   Hinderer, Christian ^b   Rodriguez, Jesse L ^b   Smith, Jenessa B ^b   Traxler, Elizabeth A ^b   Tycko, Josh ^b   Wojno, Adam P ^b   Wilson, James M ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPROTEIN LIPASE;

ADENO ASSOCIATED VIRUS; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG SCREENING; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; HYPERLIPOPROTEINEMIA TYPE 1; METABOLISM; PATHOLOGY; REVIEW;

ANIMALS; CLINICAL TRIALS AS TOPIC; DEPENDOVIRUS; DRUG EVALUATION, PRECLINICAL; GENETIC THERAPY; GENETIC VECTORS; HUMANS; HYPERLIPOPROTEINEMIA TYPE I; LIPOPROTEIN LIPASE;

EID: 84882394773     PISSN: None     EISSN: 23248645     Source Type: None    
DOI: 10.1089/humc.2013.087     Document Type: Review

References (0)